Invivo Therapeutics (NASDAQ: NVIV) and PerkinElmer (NYSE:PKI) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings.
Earnings and Valuation
This table compares Invivo Therapeutics and PerkinElmer’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Invivo Therapeutics||N/A||N/A||-$23.43 million||($0.85)||-0.61|
|PerkinElmer||$2.26 billion||3.65||$292.63 million||$1.41||53.04|
This table compares Invivo Therapeutics and PerkinElmer’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Invivo Therapeutics has a beta of 2.71, meaning that its share price is 171% more volatile than the S&P 500. Comparatively, PerkinElmer has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.
Insider and Institutional Ownership
12.0% of Invivo Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of PerkinElmer shares are owned by institutional investors. 3.9% of Invivo Therapeutics shares are owned by company insiders. Comparatively, 2.2% of PerkinElmer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
PerkinElmer pays an annual dividend of $0.28 per share and has a dividend yield of 0.4%. Invivo Therapeutics does not pay a dividend. PerkinElmer pays out 19.9% of its earnings in the form of a dividend.
This is a summary of current recommendations for Invivo Therapeutics and PerkinElmer, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Invivo Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 1,065.05%. PerkinElmer has a consensus price target of $76.08, indicating a potential upside of 1.74%. Given Invivo Therapeutics’ higher possible upside, analysts clearly believe Invivo Therapeutics is more favorable than PerkinElmer.
PerkinElmer beats Invivo Therapeutics on 11 of the 15 factors compared between the two stocks.
About Invivo Therapeutics
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets. It provides analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, lubricant, petrochemical and polymer industries. Its products include AAnalyst, Altus, Aquamatic, Avio, AxION, Clarus, DairyGuard, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, Cell carrier and cell::explorer. The Diagnostics segment is focused on reproductive health, emerging market diagnostics and applied genomics. Its products include AutoDELFIA, BACS-on-Beads, Bioo Scientific, BoBs, Datalytix, Dexela, Dexela CMOS FPDs, Evolution, ViaCord, and Zephyr.
Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.